HomeCompareDCCPF vs JNJ

DCCPF vs JNJ: Dividend Comparison 2026

DCCPF yields 4.54% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DCCPF wins by $172.2K in total portfolio value
10 years
DCCPF
DCCPF
● Live price
4.54%
Share price
$61.81
Annual div
$2.80
5Y div CAGR
41%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$202.4K
Annual income
$84,469.41
Full DCCPF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — DCCPF vs JNJ

📍 DCCPF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDCCPFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DCCPF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DCCPF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DCCPF
Annual income on $10K today (after 15% tax)
$385.52/yr
After 10yr DRIP, annual income (after tax)
$71,799.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, DCCPF beats the other by $67,813.01/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DCCPF + JNJ for your $10,000?

DCCPF: 50%JNJ: 50%
100% JNJ50/50100% DCCPF
Portfolio after 10yr
$116.3K
Annual income
$44,579.40/yr
Blended yield
38.31%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

DCCPF
Analyst Ratings
4
Buy
Consensus: Buy
Altman Z
5.8
Piotroski
7/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DCCPF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDCCPFJNJ
Forward yield4.54%2.13%
Annual dividend / share$2.80$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR41%28%
Portfolio after 10y$202.4K$30.3K
Annual income after 10y$84,469.41$4,689.40
Total dividends collected$168.3K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: DCCPF vs JNJ ($10,000, DRIP)

YearDCCPF PortfolioDCCPF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,340$639.51$10,592$272.30+$748.00DCCPF
2$13,089$955.60$11,289$357.73+$1.8KDCCPF
3$15,459$1,453.51$12,123$472.89+$3.3KDCCPF
4$18,803$2,262.15$13,141$629.86+$5.7KDCCPF
5$23,745$3,625.86$14,408$846.81+$9.3KDCCPF
6$31,441$6,033.82$16,021$1,151.60+$15.4KDCCPF
7$44,170$10,528.15$18,122$1,588.22+$26.0KDCCPF
8$66,752$19,490.33$20,930$2,228.20+$45.8KDCCPF
9$110,239$38,814.42$24,792$3,191.91+$85.4KDCCPF
10$202,425$84,469.41$30,274$4,689.40+$172.2KDCCPF

DCCPF vs JNJ: Complete Analysis 2026

DCCPFStock

DCC plc provides sales, marketing, and support services worldwide. The company's DCC LPG segment sells and markets liquefied petroleum gas (LPG), refrigerants, and natural gas. Its DCC Retail & Oil segment markets, sells, and retails transport and commercial fuels, heating oils, and related products and services; operates retail petrol stations; resells fuel cards; distributes oil; and provides inbound logistics, storage and filling, and outbound logistics services. This segment serves domestic, agricultural, commercial/industrial, forecourt, aviation, and marine customers. The company's DCC Healthcare segment offers products and services to healthcare providers, and health and beauty brand owners; outsourced contract manufacturing services to the health and beauty sector; nutrition products, such as vitamins and health supplements; beauty products; and product development, formulation, manufacturing, and packaging services. In addition, this segment procures and sells exempt medicinal products. Its DCC Technology segment distributes consumer technology products, including smart home products, gaming consoles, peripherals and software, wearable technology, and accessories; business and enterprise technology products, such as tablets, notebooks, and PCs; networking and security products; communication products comprising smartphones; and servers and storage products, audio visual products, printers, peripherals, cables and connectors, and consumables to retailers, resellers, and integrators. It also provides supply chain services. The company was founded in 1976 and is headquartered in Dublin, Ireland.

Full DCCPF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this DCCPF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DCCPF vs SCHDDCCPF vs JEPIDCCPF vs ODCCPF vs KODCCPF vs MAINDCCPF vs ABBVDCCPF vs MRKDCCPF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.